TWi Biotechnology

Executive Summary

TWi Biotechnology is a Taiwan-based biopharmaceutical company specializing in drug repurposing and novel formulation development for rare diseases, dermatology, and CNS disorders. Leveraging the FDA 505(b)(2) pathway, the company develops new indications, prodrugs, and topical formulations from existing molecules. Its lead candidate, AC-203, is a topical gel for epidermolysis bullosa simplex (EBS), a rare genetic blistering disease, and is in Phase 3 clinical trials. AC-1101 targets autoimmune skin diseases, while NORA520 is being developed for postpartum and major depressive disorders. With a lean team of 10-50 employees, TWi Biotechnology aims to efficiently advance its pipeline through regulatory pathways that reduce development timelines. The company has not yet disclosed its financials or valuation, but its focus on rare diseases and CNS disorders positions it in high-need therapeutic areas. Upcoming catalysts include data readouts and regulatory milestones that could drive significant value.

Upcoming Catalysts (preview)

• H2 2026AC-203 Phase 3 Topline Data for Epidermolysis Bullosa Simplex65% success
• H1 2027AC-1101 Phase 2 Results for Autoimmune Skin Diseases50% success
• 2027NORA520 Phase 2/3 Initiation for Postpartum Depression40% success